JP2014515735A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515735A5
JP2014515735A5 JP2013558400A JP2013558400A JP2014515735A5 JP 2014515735 A5 JP2014515735 A5 JP 2014515735A5 JP 2013558400 A JP2013558400 A JP 2013558400A JP 2013558400 A JP2013558400 A JP 2013558400A JP 2014515735 A5 JP2014515735 A5 JP 2014515735A5
Authority
JP
Japan
Prior art keywords
formula
compound
group
optionally
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013558400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014515735A (ja
JP6023097B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/054294 external-priority patent/WO2012123423A1/de
Publication of JP2014515735A publication Critical patent/JP2014515735A/ja
Publication of JP2014515735A5 publication Critical patent/JP2014515735A5/ja
Application granted granted Critical
Publication of JP6023097B2 publication Critical patent/JP6023097B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013558400A 2011-03-16 2012-03-12 Nカルボキシアルキルオーリスタチンおよびその使用 Expired - Fee Related JP6023097B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11158481 2011-03-16
EP11158481.9 2011-03-16
PCT/EP2012/054294 WO2012123423A1 (de) 2011-03-16 2012-03-12 N-carboxyalkyl-auristatine und ihre verwendung

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016145282A Division JP2016185987A (ja) 2011-03-16 2016-07-25 Nカルボキシアルキルオーリスタチンおよびその使用

Publications (3)

Publication Number Publication Date
JP2014515735A JP2014515735A (ja) 2014-07-03
JP2014515735A5 true JP2014515735A5 (enExample) 2015-07-02
JP6023097B2 JP6023097B2 (ja) 2016-11-09

Family

ID=45812791

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013558400A Expired - Fee Related JP6023097B2 (ja) 2011-03-16 2012-03-12 Nカルボキシアルキルオーリスタチンおよびその使用
JP2016145282A Withdrawn JP2016185987A (ja) 2011-03-16 2016-07-25 Nカルボキシアルキルオーリスタチンおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016145282A Withdrawn JP2016185987A (ja) 2011-03-16 2016-07-25 Nカルボキシアルキルオーリスタチンおよびその使用

Country Status (7)

Country Link
US (1) US9029406B2 (enExample)
EP (1) EP2686336B1 (enExample)
JP (2) JP6023097B2 (enExample)
CN (1) CN103764667B (enExample)
CA (1) CA2829736C (enExample)
ES (1) ES2543888T3 (enExample)
WO (1) WO2012123423A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987209B2 (en) 2010-09-29 2015-03-24 Seattle Genetics, Inc. N-carboxyalkyl-auristatin and the use thereof
SG194567A1 (en) * 2011-04-21 2013-12-30 Seattle Genetics Inc Novel binder-drug conjugates (adcs) and their use
EP2780039B9 (en) 2011-11-17 2018-04-18 Pfizer Inc Cytotoxic peptides and antibody drug conjugates thereof
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015095301A2 (en) 2013-12-17 2015-06-25 Irm Llc Cytotoxic peptides and conjugates thereof
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
MX378281B (es) 2014-04-25 2025-03-10 Pf Medicament Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
MA39909B1 (fr) 2014-04-25 2019-05-31 Pf Medicament Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
US9884817B2 (en) 2014-06-13 2018-02-06 Novartis Ag Auristatin derivatives and conjugates thereof
EP3554544A4 (en) 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE
CN111393346B (zh) * 2020-06-02 2020-08-25 凯莱英生命科学技术(天津)有限公司 N-Boc-Dolaproine及Boc-Dap DCHA的合成方法
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
ATE284412T1 (de) 1998-01-09 2004-12-15 Univ Arizona State Anti-kryptokokkus peptide
MXPA01011502A (es) 1999-05-14 2003-08-20 Boehringer Ingelheim Pharma Compuestos de tipo profarmaco anti-tumorigenos, activados por enzimas.
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6737409B2 (en) * 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド N末端にアミノ安息香酸単位を有するオーリスタチン
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
PT2845866T (pt) 2006-10-27 2017-08-09 Genentech Inc Anticorpos e imunoconjugados e utilizações dos mesmos
WO2009117531A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
CN103200950B (zh) * 2010-06-10 2016-03-16 西雅图基因公司 新颖的耳他汀衍生物及其用途
US8987209B2 (en) 2010-09-29 2015-03-24 Seattle Genetics, Inc. N-carboxyalkyl-auristatin and the use thereof
SG194567A1 (en) 2011-04-21 2013-12-30 Seattle Genetics Inc Novel binder-drug conjugates (adcs) and their use

Similar Documents

Publication Publication Date Title
ES2533356T3 (es) Compuestos de triazol que modulan la actividad de Hsp90
JP2013533228A5 (enExample)
CA2659425C (en) Triazole compounds that modulate hsp90 activity
JP2012513416A5 (enExample)
JP2014521688A5 (enExample)
JP2021513967A5 (enExample)
JP2019513770A5 (enExample)
JP2013540114A5 (enExample)
JP2009534386A5 (enExample)
JP2013532668A5 (enExample)
JP2010510999A5 (enExample)
JP2016526540A5 (enExample)
RU2020102453A (ru) Фармацевтические композиции
JP2014509600A5 (enExample)
RU2011123672A (ru) Гетероароматические соединения для применения в качестве hif ингибиторов
RU2011142154A (ru) Производные фосфлокуназола, их синтез и применение в препаратах длительного действия
JP2011516511A5 (enExample)
JP2015512943A5 (enExample)
JP2020519687A5 (enExample)
JP2019527724A5 (enExample)
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
JP2013518036A5 (enExample)
JP2017511368A5 (enExample)
JP2019507736A5 (enExample)
JP2013537240A5 (enExample)